Friedrich Baur Institute An Der Neurologischen Klinik Und Poliklinik
- Address
- lock Available on a paid plan
Neuromuscular and Nervous System Diseases
At the Friedrich Baur Institute An Der Neurologischen Klinik Und Poliklinik in Munich, research in nervous system diseases and musculoskeletal diseases focuses strongly on inherited neuromuscular disorders such as myotonic dystrophy and myotonic dystrophy type 1. These studies are designed to test new therapies, assess safety and tolerability, and explore whether treatments can improve symptoms like muscle stiffness and hand myotonia.
- Investigating myotonic dystrophy type 1 with a focus on treatment safety and symptom improvement
- Evaluating whether new therapies can reduce hand myotonia and support daily function
- Studying long-term treatment effects in chronic neuromuscular disease
Several trials here aim to better understand how emerging medicines may help people living with these progressive genetic conditions.
Metabolic and Lysosomal Disorders
Research in nutritional and metabolic diseases and congenital and hereditary disorders includes studies of Fabry disease, Pompe disease, and primary mitochondrial disease. The main goal is to evaluate new treatments that may ease pain, improve muscle or heart-related symptoms, and support better disease control in rare inherited conditions.
- Assessing therapies for Fabry disease to help with neuropathic and abdominal pain
- Testing treatment options for late-onset Pompe disease with attention to safety and tolerability
- Exploring approaches for primary mitochondrial disease linked to myopathy and cardiomyopathy
These trials reflect a broad effort to improve care for rare metabolic diseases through better symptom management and therapeutic development.
Rare Disease Therapeutics
The site also contributes to research on rare genetic diseases by studying treatments aimed at underlying disease mechanisms rather than only symptoms. Across these projects, investigators are evaluating whether new medicines can be safely used and whether they may lead to meaningful clinical benefit in conditions with limited treatment options.
- Testing new therapies for inherited disorders with few established treatment choices
- Measuring safety, tolerability, and early signs of effectiveness
- Supporting development of targeted care for patients with complex multisystem disease
The research portfolio at this clinical trial site is centered on improving outcomes for patients with challenging and often long-term neurological and metabolic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Vertex Pharmaceuticals Inc.2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Vertex Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Friedrich Baur Institute An Der Neurologischen Klinik Und Poliklinik
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Safety, Tolerability, and Efficacy of Intravenous Vanglusagene Ensiparvovec in Adults with Late-Onset Pompe Disease | Genentech Inc. | Phase I/II | Recruiting | Oct 2021 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vx-670 | 2 | Unknown | 2024-12-11 | 2025-11-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.